Onconova Therapeutics Inc... (ONTX)
NASDAQ: ONTX
· Real-Time Price · USD
1.00
0.00 (0.00%)
At close: Apr 02, 2024, 10:00 PM
Onconova Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 20.55B | 21.49B | -166,523B | -127.43M | -4.98M | -4.18M | -4.74M | -4.25M | -5.78M | -5.42M | -5.4M | -4.02M | -4.12M | -3.76M | -3.45M | -4.23M | -4.71M |
Depreciation & Amortization | 2M | 1M | 12B | 2K | 4K | 4K | 5K | 4K | 3K | 4K | 3K | 4K | 3K | 4K | 3K | 4K | 3K |
Stock-Based Compensation | 265.84M | 161M | 1,390B | 391K | 333K | 332K | 360K | 273K | 336K | 330K | 305K | 241K | 296K | 261K | 190K | 60K | 65K |
Other Working Capital | 82K | n/a | 1.28M | 109K | -56K | -53K | -1.17M | -692K | -155K | 1.1M | 433K | -316K | -838K | -56K | -237K | -15K | -56K |
Other Non-Cash Items | -32.23B | -27.09B | 135,329B | 108.3M | n/a | -301B | -706K | -72K | -706K | 1,484B | -446K | 369K | n/a | -3,914B | -530K | -427K | 636K |
Deferred Income Tax | n/a | n/a | 778K | 1.48M | n/a | -1.48M | 706K | 72K | 706K | -1,484B | 446K | -369K | n/a | 3,914B | n/a | n/a | n/a |
Change in Working Capital | 576K | n/a | 455K | 360K | 222K | -582K | -95K | -517K | 893K | 1.2M | 1.19M | -435K | -473K | -766K | -477K | 287K | -2.64M |
Operating Cash Flow | -11.41B | -5.44B | -29,792B | -16.9M | -4.42M | -4.43M | -4.47M | -4.49M | -4.54M | -3.88M | -3.9M | -4.21M | -4.3M | -4.26M | -4.27M | -4.31M | -6.65M |
Capital Expenditures | n/a | n/a | 14B | 14B | n/a | -14B | -14K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | -3,648B | -3.65M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | 19,977B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | -19,977B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | -3,634B | 14B | n/a | -14B | -14K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 3.11B | 13M | 19,977B | 14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -35K | 19.94M | 7K | 35.64M |
Financial Cash Flow | 3.11B | 13M | 33,976B | 14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -35K | 19.94M | 7K | 35.64M |
Net Cash Flow | 13.07B | -5.4B | 21,338B | -10.98M | -4.43M | -4.42M | -4.49M | -4.49M | -4.54M | -3.86M | -3.92M | -4.23M | -4.3M | -4.31M | 15.67M | -4.3M | 28.98M |
Free Cash Flow | -11.41B | -5.44B | -29,778B | 13.98B | -4.42M | -14B | -4.48M | -4.49M | -4.54M | -3.88M | -3.9M | -4.21M | -4.3M | -4.26M | -4.27M | -4.31M | -6.65M |